NCT00690092 - A Multi-center Study of Spherule-Derived Coccidioidin | Biotech Hunter

Enrollment

113

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Coccidioidomycosis

Interventions

BIOLOGICAL

Spherule-derived coccidioidin

1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.

Trial Locations (4)

68001

Blair Clinic, Blair

85723

Health Sciences Center AVAHCS, Univ. of Arizona, Tucson

93306

Kern Facility Medical Group, Bakersfield

99204

Spokane Allergy and Asthma Center, Spokane